Frontier Pharma: Transplantation Therapeutics - A Highly Innovative Pipeline with a Range of Adaptive and Innate Immune-Targeting Programs Focusing on Graft-Versus-Host Disease and Kidney Transplantation

Market: Pharmaceuticals and Healthcare

Global, 72 pages report, published by GBI Research

Report ThumbnailDecember-2017
Frontier Pharma: Transplantation Therapeutics - A Highly Innovative Pipeline with a Range of Adaptive and Innate Immune-Targeting Programs Focusing on Graft-Versus-Host Disease and Kidney Transplantation

Summary

In 2015 a total of 127,000 transplantations were performed worldwide, an increase of 5.8% from 2014, with 33,000 of these occurring in the EU and 32,000 in the US. Approximately 60% of these were kidney transplants, with liver, heart, lung, pancreas and small bowel transplantations acc

Read More
  • 1.2 List of Figures
  • Figure 1: Transplantation Therapeutics, US, Innovation Trends in Product Approvals, 1987-2014 6
  • Figure 2: Transplantation Therapeutics, US, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006-2013 8
  • Figure 3: Transplantation Therapeutics, Global, Overview of Marketed Products, 2017 22
  • Figure 4: Transplantation Therapeutics, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017 24
  • Figure 5: Transplantation Therapeu
Read More
  • 1.1 List of Tables
  • Table 1: Transplantation Therapeutics, Global, Organ-Specific Symptoms of Transplant Rejection, 2017 11
  • Table 2: Transplantation Therapeutics, Global, Organ-Specific Symptoms of Acute GVHD, 2017 12
  • Table 3: Transplantation Therapeutics, Global, Organ-Specific Symptoms of Acute GVHD, 2017 12
  • Table 4: Transplantation Therapeutics, Global, Key Features of C-X-C Chemokine Receptor Type 1, 2017 40
  • Table 5: Transplantation Therapeutics, Global, Key Features of C-X-C Chemokine Recept
Read More
  • 1 Table of Contents
  • 1 Table of Contents 2
  • 1.1 List of Tables 3
  • 1.2 List of Figures 3
  • 2 Executive Summary 5
  • 2.1 Strong Unmet need for Prevention of Chronic Rejection 5
  • 2.2 Moderately-Sized by Highly Innovative Pipeline 5
  • 2.3 Chemokines and Immune Surface Antigens Appear to Hold Promise as Novel Targets 5
  • 3 The Case for Innovation 6
  • 3.1 Growing Opportunities for Biologic Products 7
  • 3.2 Diversification of Molecular Targets 7
  • 3.3 Innovative First-in-Class Product Developments Remain Attractive 7
  • 3.4
Read More

Related Products

GBI ResearchFrontier Pharma: Transplantation Therapeutics - A Highly Innovative Pipeline with a Range of Adaptive and Innate Immune-Targeting Programs Focusing on Graft-Versus-Host Disease and Kidney TransplantationProduct ThumbnailFrontier Pharma: Transplantation Therapeutics - A Highly Innovative Pipeline with a Range of Adaptive and Innate Immune-Targeting Programs Focusing on Graft-Versus-Host Disease and Kidney Transplantation, Industry ReportProduct #: 1121867
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2018 Global Market Analyst. All Rights Reserved